Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Minghuan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Antipsychotic Drugs and Cognitive Function
Lena Feber, Natalie Peter, Virginia Chiocchia, et al.
JAMA Psychiatry (2024)
Closed Access | Times Cited: 9
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database
Haohao Zhu, Yucai Qu, Zhiqiang Du, et al.
Journal of Affective Disorders (2023) Vol. 347, pp. 45-50
Closed Access | Times Cited: 22
The Role of Gasotransmitter-Dependent Signaling Mechanisms in Apoptotic Cell Death in Cardiovascular, Rheumatic, Kidney, and Neurodegenerative Diseases and Mental Disorders
Stanislav Rodkin, Chizaram Nwosu, Alexander Sannikov, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6014-6014
Open Access | Times Cited: 17
Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects
Chelsea Boydstun, Sean Lynch, Patrick DiGenova
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 361-366
Closed Access | Times Cited: 11
Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses
Surojit Karmakar, Girdhari Lal
Methods in molecular biology (2024), pp. 181-207
Closed Access | Times Cited: 4
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Prakash S. Masand, Mousam Parikh, Jamie T. Ta, et al.
Journal of Medical Economics (2025), pp. 1-29
Open Access
Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine
Alessandro Cuomo, Giovanni B. Forleo, Taieb Ghodhbane, et al.
Annals of General Psychiatry (2025) Vol. 24, Iss. 1
Open Access
ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents
Omar Soler‐Cedeño, Bradley M. Keegan, Hannah Alton, et al.
British Journal of Pharmacology (2025)
Open Access
Digital therapeutics for cognitive impairments associated with schizophrenia: our opinion
Shengtao Sun, C. Salazar Li, Xueguang Xie, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access
Schizophrenia: Antipsychotics and drug development
Gary Remington, Margaret Hahn, Sri Mahavir Agarwal, et al.
Behavioural Brain Research (2021) Vol. 414, pp. 113507-113507
Closed Access | Times Cited: 25
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 18
A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder
Ewa Galaj, Guo‐Hua Bi, Benjamin Klein, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 13, pp. 2309-2318
Open Access | Times Cited: 17
Multilevel evidence of MECP2-associated mitochondrial dysfunction and its therapeutic implications
Péter Balicza, András Gézsi, Mariann Fedor, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 3
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations
Antonio Vita, Sergio Barlati, Roberto Cavallaro, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
Adam Montgomery, Marianna Rogowska, Luiz Dratcu
Clinical Psychopharmacology and Neuroscience (2023) Vol. 21, Iss. 1, pp. 202-206
Open Access | Times Cited: 8
Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
André Do, Kamyar Keramatian, Ayal Schaffer, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 15
Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder
Mats Bogren, Monica Soltesz, Stephan Hjorth
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 10
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder
Heinz Grunze
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 1985-1992
Closed Access | Times Cited: 6
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
Octavian Vasiliu
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 14
Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
Réka Csehi, Z.B. Dombi, B. Sebe, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 9
Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders
Emma Gogarnoiu, Caleb D. Vogt, Julie Sanchez, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1809-1834
Open Access | Times Cited: 5
Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System
Heinz Grunze, Réka Csehi, Christoph Born, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 12
Mini Review on Cariprazine: A Promising Antipsychotic Agent
Ashish Patel, Arya Patel, Darshini Patel, et al.
CNS & Neurological Disorders - Drug Targets (2022) Vol. 22, Iss. 2, pp. 226-236
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top